Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL

Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care

Shilpa Medicare lunches pemetrexed injection in India under the brand name VRTU

Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India

Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.

Lupin Digital Health and American College of Cardiology collaborate for in-home cardiovascular care in India

Akums gets approval for triple combination diabetes treatment

CARER collaborates with Wholeleaf to enhance holistic cancer care services

The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being

Alkem forays into ophthalmology with launch of eye care products

Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc

Croda completes acquisition of Solus Biotech

This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments